Buy Valeant Pharmaceuticals (VRX) Ahead of Investor Day Catalyst - Guggenheim

Bill Ackman 'has killed Pershing Square. Its over'- Hempton (VRX)

November 23, 2015 6:03 PM EST

John Hempton says Bill Ackman "has killed Pershing Square. Its over." following news the firm raised its stake in Valeant Pharmaceuticals (NYSE: VRX) to 9.9%.

Bill Ackman has killed Pershing Square. Its over... https://t.co/1pp5XSHRme

John_Hempton (@John_Hempton) November 23, 2015... More

Exclusive: ValueAct gains for the year wiped out by Valeant loss

November 23, 2015 5:48 PM EST

By Michael Flaherty

(Reuters) - Activist investor ValueAct Capital said its fund fell 8.3 percent during the third quarter, wiping out its gains for the year, hurt by a plunge in shares of its main portfolio company, Valeant Pharmaceuticals International Inc (NYSE: VRX).

For the nine months ending on Sept. 30, the ValueAct Capital Master Fund was down 0.9 percent, ValueAact said in a letter to investors which was seen by Reuters on Monday. As of the second quarter, the fund had been up 8 percent for the year.

ValueAct also said it... More

Ackman boosts stake in drugmaker Valeant

November 23, 2015 5:44 PM EST

(Reuters) - Activist investor Bill Ackman's hedge fund has significantly increased its investment in Valeant Pharmaceuticals International (NYSE: VRX), and signaled it may play a greater role in the beleaguered drugmakers strategy, according to a regulatory filing.

Ackman's Pershing Square Capital Management raised its stake in Valeant to 9.9 percent from 5.7 percent reported in March, according to a filing on Monday with the U.S. Securities and Exchange Commission. Shares in the company rose 3.1 percent in after-hours trading.

Pershing noted in its filing that it may conduct... More

Pershing Square Capital Affirms Lifting Valeant Pharma (VRX) Stake to 9.9%

November 23, 2015 5:28 PM EST

Pershing Square Capital Management, L.P., the investment manager for Pershing Square Holdings, Ltd. has updated its Schedule 13D with the United States Securities and Exchange Commission, disclosing that various funds it manages increased their beneficial ownership of Valeant Pharmaceuticals International, Inc. (NYSE: VRX), to 9.9% of shares outstanding.

... More

Market Wrap: Pfizer, Allergan Make it Offiical; Icahn Gets Active on Xerox; Existing Sales Slump in Oct.

November 23, 2015 5:26 PM EST

Market wrap for November 23rd

End of the Day: S&P 500 down 2.6 to 2,086.59; Dow Jones down to 17,792.68; Nasdaq down 2.4 to 5,102.48

Market Brief: Markets ended lower to start off the holiday-shortened week with most investors now looking to a December rate hike from the Fed. Trading on the session was notably light.

Existing home sales slipped in October, missing consensus estimates in the process.

Pfizer and Allergan announced a massive merger agreement, bolstering a slew of other M&A... More

Ackman's Pershing Square Capital Raises Stake in Valeant Pharmaceuticals (VRX) to 9.9%

November 23, 2015 5:17 PM EST

In an amended 13D filing on Valeant Pharmaceuticals (NYSE: VRX), Bill Ackman's hedge fund Pershing Square Capital disclosed a 9.9%, or 34,118,551 share, stake in the company. This is up 75.20% from the 19,473,933 shares held at the end of the latest quarter ending September 30, 2015.

For more notable holders of Valeant Pharmaceuticals stock click here. For more information on Pershing Square Capital click... More

Ackman's Pershing Square Moves Stake in Valeant Pharma (VRX) to 9.9%

November 23, 2015 5:17 PM EST

In an amended 13D filing on Valeant Pharma (NYSE: VRX), Bill Ackman's hedge fund Pershing Square Capital disclosed a 9.9%, or 34,118,551 share, stake in the company. This is up 75.20% from the 19,473,933 shares held at the end of the latest quarter ending September 30, 2015.

More from the amended filing:

The Reporting Persons hold their stake in the Issuer for investment purposes. Representatives of the Reporting Persons may conduct discussions from time to time with management of the Issuer, other stockholders of the Issuer and/or other relevant... More

Pershing Square Capital Raises Stake in Valeant Pharma (VRX) to 9.9%

November 23, 2015 5:16 PM EST

In a 13D filing on Valeant Pharma (NYSE: VRX), hedge fund Pershing Square Capital disclosed a 9.9%, or 34,118,551 share, stake in the company. This is up 75.20% from the 19,473,933 shares held at the end of the latest quarter ending September 30, 2015.

For more notable... More

Hedge funds' favorite stocks lag broader market: Goldman data

November 23, 2015 4:29 PM EST

By Svea Herbst-Bayliss

BOSTON (Reuters) - Hedge fund managers' favorite stocks stumbled hard this year to post their worst returns since the financial crisis with health-care companies, such as Valeant Pharmaceuticals (NYSE: VRX), leading the way lower, according to new data from Goldman Sachs.

Goldman analysts calculated that the basket of managers' 50 most heavily owned stocks - among which are Allergan (NYSE: AGN), Facebook (NASDAQ: FB), Netflix (NASDAQ: NFLX) and Cheniere Energy (NYSE:... More

Left for Dead Valeant Pharma (VRX) Is Up 30% In a Week

November 23, 2015 10:43 AM EST

Short seller target Valeant Pharma (NYSE: VRX) is continuing to rally sharply off oversold conditions following a few modest positives over the past week or so:

Citi launched coverage on the... More